Business Description
Kiniksa Pharmaceuticals Ltd
NAICS : 325412
SIC : 2836
ISIN : BMG5269C1010
Share Class Description:
KNSA: Class ADescription
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.42 | |||||
| Equity-to-Asset | -0.95 | |||||
| Debt-to-Equity | -0.03 | |||||
| Debt-to-EBITDA | -0.43 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 8.31 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 49.7 | |||||
| 3-Year Book Growth Rate | 10.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.35 | |||||
| 9-Day RSI | 51.65 | |||||
| 14-Day RSI | 44.92 | |||||
| 6-1 Month Momentum % | 30.27 | |||||
| 12-1 Month Momentum % | 73.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Days Inventory | 185.48 | |||||
| Days Sales Outstanding | 16.7 | |||||
| Days Payable | 28.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | -0.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 83.61 | |||||
| Operating Margin % | -10.12 | |||||
| Net Margin % | 2.87 | |||||
| FCF Margin % | 4.87 | |||||
| ROE % | 3.76 | |||||
| ROA % | 1.76 | |||||
| ROIC % | 4.53 | |||||
| ROC (Joel Greenblatt) % | -161.82 | |||||
| ROCE % | -6.77 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 99.56 | |||||
| PE Ratio without NRI | 99.56 | |||||
| PS Ratio | 4.79 | |||||
| Price-to-Free-Cash-Flow | 98.54 | |||||
| Price-to-Operating-Cash-Flow | 97 | |||||
| EV-to-EBIT | -42.59 | |||||
| EV-to-EBITDA | -46.96 | |||||
| EV-to-Revenue | 3.97 | |||||
| EV-to-FCF | 81.46 | |||||
| Price-to-Net-Current-Asset-Value | 10.12 | |||||
| Price-to-Net-Cash | 10.12 | |||||
| Earnings Yield (Greenblatt) % | -2.35 | |||||
| FCF Yield % | 1.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KNSA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kiniksa Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 270.259 | ||
| EPS (TTM) ($) | 0.18 | ||
| Beta | 0.1 | ||
| Volatility % | 50.26 | ||
| 14-Day RSI | 44.92 | ||
| 14-Day ATR ($) | 0.636382 | ||
| 20-Day SMA ($) | 17.92375 | ||
| 12-1 Month Momentum % | 73.05 | ||
| 52-Week Range ($) | 10.645 - 22.09 | ||
| Shares Outstanding (Mil) | 70.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kiniksa Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kiniksa Pharmaceuticals Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kiniksa Pharmaceuticals Ltd Frequently Asked Questions
What is Kiniksa Pharmaceuticals Ltd(KNSA)'s stock price today?
The current price of KNSA is $17.92. The 52 week high of KNSA is $22.09 and 52 week low is $10.65.
When is next earnings date of Kiniksa Pharmaceuticals Ltd(KNSA)?
The next earnings date of Kiniksa Pharmaceuticals Ltd(KNSA) is 2024-07-25 Est..
Does Kiniksa Pharmaceuticals Ltd(KNSA) pay dividends? If so, how much?
Kiniksa Pharmaceuticals Ltd(KNSA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers